Tekia's presbyopia intraocular lens:
This article was originally published in Clinica
Tekia has CE-marked for sale in Europe its accommodating intraocular lens for treating presbyopia. The implantable device uses the eye's ocular structures to shift the lens forward, enabling a person to see close up, and then shift back to the resting position so the person will see distant objects. In the US, the Irvine, California firm expects to submit to the FDA later this year an application to test the lens in clinical studies; to fund the FDA approval process the firm expects to pursue financing options and/or a strategic partner to provide additional resources. Tekia currently distributes in Europe and in certain South American countries its Kelman Duet refractive IOL for treating myopia and hyperopia in non-cataract patients.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.